671. Why Has There Been So Little Progress on Alzheimer’s Disease?

What It Covers

Investigative journalist Charles Pillar and Vanderbilt neuroscientist Matthew Schrag expose decades of manipulated research underpinning Alzheimer's dominant amyloid cascade hypothesis. Despite $4 billion in annual NIH funding, no drug arrests cognitive decline. The episode traces fraud from Cassava Sciences through a 132-paper dossier implicating the NIH's own neuroscience division chief.

Key Questions Answered

• •Amyloid Hypothesis Dominance: Since roughly 1990, Alzheimer's research has concentrated almost entirely on beta-amyloid plaque as the primary disease driver, directing the majority of clinical trial funding toward anti-amyloid antibody drugs. Two FDA-approved drugs in this class produce effects so marginal that clinicians, patients, and families often cannot perceive any cognitive improvement, yet no patient reverses decline on these treatments.
• •Research Fraud Detection Method: Forensic image analysis of western blot photographs can reveal data manipulation — copy-pasted regions, duplicated neurons, and altered pixel intensity — that systematically shifts experimental results to support a hypothesis. Schrag and four independent forensic experts used this technique to identify irregularities across 132 of roughly 800 papers reviewed from one researcher alone, building 300-page dossiers submitted to NIH.
• •Regulatory Capture at FDA: Eleven of 16 FDA medical examiners who worked on Alzheimer's drug approvals subsequently took employment or consulting roles at the companies they regulated. The aducanumab approval — a drug later withdrawn for being dangerous and ineffective — resulted from documented collaboration between the FDA's oversight official and the drug's manufacturer, illustrating how the revolving door distorts approval decisions.
• •Waste Clearance Reformulation: Schrag proposes reframing Alzheimer's as a disease of failed brain waste clearance rather than a single-protein cascade. Beta-amyloid and tau tangles are both waste products; blood vessel degeneration slows their removal. Supporting this, clinical trials show aggressive blood pressure control measurably protects memory in early-stage patients, suggesting vascular health intervention as a concrete, underexplored treatment target.
• •Institutional Accountability Gap: When NIH refers misconduct allegations back to the university where the accused researcher works, investigations become opaque and slow. In the Lesney case at the University of Minnesota, the implicated researcher continued collecting hundreds of thousands in federal grants for years during review, published additional papers with apparent manipulations, and ultimately resigned without public disclosure of investigation findings.
• •Environmental and Socioeconomic Risk Factors: Alzheimer's prevalence correlates with air pollution exposure, obesity, and lower educational attainment — making it partly a disease of inequality. Higher educational attainment demonstrably reduces severity and delays onset. These modifiable population-level factors receive far less research funding than pharmaceutical interventions, representing an actionable prevention gap that policymakers and researchers could address independently of drug development.